Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 7;6(1):e1255395. doi: 10.1080/2162402X.2016.1255395

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 1. — EBX peptide inhibits polyp formation. (A) Schematic showing relation of EBX peptide (ERBB3 residues 299–325) and EB3IV recombinant protein (ERBB3 residues 269–396) to ERBB3 extracellular domain (ECD). (B) Polyp burden in 100 day old Apc^Min mice after no treatment (NIC) or treatment with carrier protein (KLH), recombinant protein (EB3IV) or peptide (EBX). Mice were treated at 3, 5, and 9 weeks following birth. The dashed line represents the mean for each group. (C) Mean polyp burden for different portions of the intestinal tract from Apc^Min mice treated with KLH, EB3IV, EBX, or control. (D) Erbb3 activation assay in SW620 cells with (+) or without (−) 12.5 nM neuregulin in the presence of sera from two separate EBX-or KLH-immunized mice. All error bars show means ± SEM Statistics: ^‡p < 0.001; **p < 0.01.